The efficacy and tolerability of a CO (2)-extract of feverfew (MIG-99, 6.25 mg t.i.d.) for migraine prevention were investigated in a randomized, double-blind, placebo-controlled, multicentre, parallel-group study.

MIG-99 (feverfew) is probably effective for migraine prevention (1 Class I study, 1 positive Class II study, and 1 underpowered negative Class II study). The efficacy of HBO for migraine prevention is unclear (1 imprecise negative Class II study).

After a four‐week screening period without migraine prophylaxis, 218 participants were randomised to receive either 6.25 mg of a feverfew CO 2 ‐extract (MIG‐99, n = 108) or placebo (n = 110) three times daily for 16 weeks. Patients documented each migraine attack in a diary.

Aug 22, 2024 · Feverfew is primarily known for use in prophylaxis of migraine headaches and associated nausea and vomiting; however, evidence regarding this use is inconclusive. An optimal dose of feverfew has not been established.

The primary objective was to show a dose-response of a new stable extract (MIG-99) reproducibly manufactured with supercritical CO2 from feverfew (T. parthenium). Furthermore, the study should provide data on the safety and tolerability of MIG-99.

The primary objective was to show a dose-response of a new stable extract (MIG-99) reproducibly manufactured with supercritical CO 2 from feverfew (T. parthenium). Furthermore, the study should provide data on the safety and tolerability of MIG-99.

efficacy of MIG-99 in reducing the frequency of migraine attacks in migraine at a minimum dose of 6.25 mg extract t.i.d. (14). Despite the statistically sig-nificant difference in favour of MIG-99, the results needed to be confirmed and replicated in a second placebo-controlled study in more patients. Methods Study design

The efficacy and tolerability of a CO (2)-extract of feverfew (MIG-99, 6.25 mg t.i.d.) for migraine prevention were investigated in a randomized, double-blind, placebo-controlled, multicentre, parallel-group study.

The Mikoyan-Gurevich MiG-9 (Russian: Микоян и Гуревич МиГ-9, USAF/DoD designation: Type 1, NATO reporting name: Fargo[1]) was the first turbojet fighter developed by Mikoyan-Gurevich in the years immediately after World War II. It used reverse-engineered German BMW 003 engines.

One review found strong evidence for butterbur (Petasites) and moderate evidence for feverfew (MIG-99) as well as NSAIDs like ibuprofen (Neurology, Apr. 24, 2012). In conclusion, all of these work best if taken before the pain begins or at the very first sign of migraine.